(Q35121710)

6 August 2017

1 reference

title

Aetiology of bone disease and the role of bisphosphonates in multiple myeloma (English)

1 reference

6 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01076-3

30 December 2023

2

Faith E. Davies

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12732166

30 December 2023

3

Gareth J. Morgan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12732166

30 December 2023

author name string

Andrew J. Ashcroft

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12732166

30 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12732166

30 December 2023

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S1470204503010763?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01076-3

https://api.elsevier.com/content/article/PII:S1470204503010763?httpAccept=text/plain

30 December 2023

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01076-3

Lancet Oncology Commission

30 December 2023

published in

1 reference

6 August 2017

volume

4

1 reference

6 August 2017

issue

5

1 reference

6 August 2017

page(s)

284-292

1 reference

Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Economic impact of using clodronate in the management of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Immunocytochemistry reveals RANKL expression of myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

New insights into role of microenvironment in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Evidence for the secretion of an osteoclast stimulating factor in myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumor in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Two squamous cell carcinomas not associated with humoral hypercalcemia produce a potent bone resorption-stimulating factor which is interleukin-1 alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Parathyroid hormone-related protein and interleukin-1 alpha synergistically stimulate bone resorption in vitro and increase the serum calcium concentration in mice in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Bisphosphonates induce breast cancer cell death in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Bisphosphonates induce apoptosis in human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Long-Term Effects of Dichloromethylene Diphosphonate (Cl2 DP) on skeletal Lesions in Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Diagnosis and management of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Stimulation of bone formation in vitro and in rodents by statins

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901076-3

7 January 2021

Modulation of osteoclast differentiation

4

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01076-3

Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma

30 December 2023

36

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01076-3

Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies

30 December 2023

37

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01076-3

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway

30 December 2023

43

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01076-3

Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases

30 December 2023

47

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01076-3

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial

30 December 2023

61

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01076-3

Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer

30 December 2023

65

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01076-3

30 December 2023

Identifiers

1 reference

6 August 2017

1 reference